Business Description
Pharmesis International Ltd
ISIN : SG1BH6000003
Compare
Compare
Traded in other countries / regions
BFK.Singapore IPO Date
2004-10-06Description
Pharmesis International Ltd is an investment holding company. The company manufactures pharmaceutical products in the form of tablets, granules, pills, and other forms. Its operating segments are Western drugs/TCH Procurement, which are chemically formulated drugs and are marketed under the Kinna brand; TCM-formulated drugs/IP rental, which refer to Traditional Chinese Medicine and are marketed under the Longlife brand; and Distribution, which derives maximum revenue, refers to agency products and internally manufactured products which are marketed through the distribution arm. The company derives revenue from the sale of medicines to domestic customers in China.
Financial Strength
3/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Cash-To-Debt | 0.28 | |||||
Equity-to-Asset | 0.58 | |||||
Debt-to-Equity | 0.28 | |||||
Debt-to-EBITDA | -36.87 | |||||
Piotroski F-Score | 4/9 | |||||
Altman Z-Score | 0.71 | |||||
Beneish M-Score | 8.17 | |||||
WACC vs ROIC | ||||||
Growth Rank
1/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
3-Year Revenue Growth Rate | -15.9 | |||||
3-Year EPS without NRI Growth Rate | 5.9 | |||||
3-Year FCF Growth Rate | -35.8 | |||||
3-Year Book Growth Rate | -10.9 |
Momentum Rank
5/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
5-Day RSI | 44.95 | |||||
9-Day RSI | 25.73 | |||||
14-Day RSI | 20.26 | |||||
3-1 Month Momentum % | 16.9 | |||||
6-1 Month Momentum % | 43.1 | |||||
12-1 Month Momentum % | -10.75 |
Liquidity Ratio
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Current Ratio | 0.96 | |||||
Quick Ratio | 0.55 | |||||
Cash Ratio | 0.11 | |||||
Days Inventory | 196.92 | |||||
Days Sales Outstanding | 160.35 | |||||
Days Payable | 183.54 |
Dividend & Buy Back
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
3-Year Average Share Buyback Ratio | -11.3 | |||||
Shareholder Yield % | 3.89 |
Profitability Rank
2/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Gross Margin % | 36.16 | |||||
Operating Margin % | -12.25 | |||||
Net Margin % | -9.91 | |||||
EBITDA Margin % | -0.99 | |||||
FCF Margin % | 0.7 | |||||
OCF Margin % | 4.59 | |||||
ROE % | -7.25 | |||||
ROA % | -4.27 | |||||
ROIC % | -6.73 | |||||
3-Year ROIIC % | 41.81 | |||||
ROC (Joel Greenblatt) % | -7.98 | |||||
ROCE % | -5.54 | |||||
Years of Profitability over Past 10-Year | 3 |
GF Value Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Price-to-Owner-Earnings | 15.22 | |||||
PS Ratio | 0.43 | |||||
PB Ratio | 0.33 | |||||
Price-to-Tangible-Book | 0.35 | |||||
Price-to-Free-Cash-Flow | 107 | |||||
Price-to-Operating-Cash-Flow | 8.92 | |||||
EV-to-EBIT | -9.21 | |||||
EV-to-EBITDA | -71.18 | |||||
EV-to-Revenue | 0.71 | |||||
EV-to-FCF | 118.42 | |||||
Price-to-GF-Value | 1.19 | |||||
Price-to-Projected-FCF | 0.63 | |||||
Price-to-Median-PS-Value | 1.07 | |||||
Earnings Yield (Greenblatt) % | -10.82 | |||||
FCF Yield % | 1.63 | |||||
Forward Rate of Return (Yacktman) % | 8.82 |
Operating Revenue by Business Segment
Operating Revenue by Geographic Region
Historical Operating Revenue by Business Segment
Historical Operating Revenue by Geographic Region
Guru Trades
See DetailsInsider Trades
See DetailsPeter Lynch Chart
Performance
Dividend
Log
Bar
Annualized Return % Â
Total Annual Return % Â
Pharmesis International Ltd Executives
DetailsAnalyst Estimate
Key Statistics
| Name | Value | ||
|---|---|---|---|
| Revenue (TTM) (Mil S$) | 7.892 | ||
| EPS (TTM) (S$) | -0.025 | ||
| Beta | -3.0007 | ||
| 3-Year Sharpe Ratio | 0.41 | ||
| 3-Year Sortino Ratio | 1.11 | ||
| Volatility % | 83.33 | ||
| 14-Day RSI | 20.26 | ||
| 14-Day ATR (S$) | 0.009756 | ||
| 20-Day SMA (S$) | 0.1314 | ||
| 12-1 Month Momentum % | -10.75 | ||
| 52-Week Range (S$) | 0.077 - 0.465 | ||
| Shares Outstanding (Mil) | 31.7 |
Piotroski F-Score Details
Year:
| Component | Result | ||
|---|---|---|---|
| Piotroski F-Score | 4 | ||
| Positive ROA | |||
| Positive CFROA | |||
| Higher ROA yoy | |||
| CFROA > ROA | |||
| Lower Leverage yoy | |||
| Higher Current Ratio yoy | |||
| Less Shares Outstanding yoy | |||
| Higher Gross Margin yoy | |||
| Higher Asset Turnover yoy |
Pharmesis International Ltd Filings
| Filing Date | Document Date | Form | ||
|---|---|---|---|---|
| No Filing Data | ||||
Pharmesis International Ltd Stock Events
| Event | Date | Price (S$) | ||
|---|---|---|---|---|
| SGD 0.010000 Cash Dividend | 2026-07-20 | 0.14 (+0.00%) | ||
| SGD 0.010000 Cash Dividend | 2025-08-20 | 0.47 (+0.00%) | ||
| 0.1:1 Stock Split | 2015-08-27 | 0.35 (+0.00%) |
Show
Entries
Pharmesis International Ltd Frequently Asked Questions
What is Pharmesis International Ltd(SGX:BFK)'s stock price today?
The current price of SGX:BFK is S$0.11. The 52 week high of SGX:BFK is S$0.47 and 52 week low is S$0.08.
When is next earnings date of Pharmesis International Ltd(SGX:BFK)?
The next earnings date of Pharmesis International Ltd(SGX:BFK) is .
Does Pharmesis International Ltd(SGX:BFK) pay dividends? If so, how much?
Pharmesis International Ltd(SGX:BFK) does not pay dividend.
Press Release
| Subject | Date | |||
|---|---|---|---|---|
| No Press Release | ||||
Articles on Pharmesis International Ltd
No articles.
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers